Clinical trial
Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV…
NCT00261027 · Ottawa Hospital Research Institute, Other · Completed
Key facts
| NCT number | NCT00261027 |
|---|---|
| Title | Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer |
| Official title | A Pilot, Phase II, Single Center, Non-comparative, Open-label Study of Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer |
| Lead sponsor | Ottawa Hospital Research Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Exemestane |
| Enrollment | 30 |
| Start date | Jan 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Dec 2, 2005 |
| Last update posted | Mar 2, 2010 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: